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ABSTRACT
Purpose To determine the potential associations 
between physical activity and risk of SARS- CoV-2 
infection, severe illness from COVID-19 and COVID-19 
related death using a nationwide cohort from South 
Korea.
Methods Data regarding 212 768 Korean adults (age 
≥20 years), who tested for SARS- CoV-2, from 1 January 
2020 to 30 May 2020, were obtained from the National 
Health Insurance Service of South Korea and further 
linked with the national general health examination 
from 1 January 2018 to 31 December 2019 to assess 
physical activity levels. SARS- CoV-2 positivity, severe 
COVID-19 illness and COVID-19 related death were the 
main outcomes. The observation period was between 1 
January 2020 and 31 July 2020.
Results Out of 76 395 participants who completed 
the general health examination and were tested for 
SARS- CoV-2, 2295 (3.0%) were positive for SARS- CoV-2, 
446 (0.58%) had severe illness from COVID-19 and 45 
(0.059%) died from COVID-19. Adults who engaged 
in both aerobic and muscle strengthening activities 
according to the 2018 physical activity guidelines had 
a lower risk of SARS- CoV-2 infection (2.6% vs 3.1%; 
adjusted relative risk (aRR), 0.85; 95% CI 0.72 to 0.96), 
severe COVID-19 illness (0.35% vs 0.66%; aRR 0.42; 
95% CI 0.19 to 0.91) and COVID-19 related death 
(0.02% vs 0.08%; aRR 0.24; 95% CI 0.05 to 0.99) than 
those who engaged in insufficient aerobic and muscle 
strengthening activities. Furthermore, the recommended 
range of metabolic equivalent task (MET; 500–1000 MET 
min/week) was associated with the maximum beneficial 
effect size for reduced risk of SARS- CoV-2 infection (aRR 
0.78; 95% CI 0.66 to 0.92), severe COVID-19 illness 
(aRR 0.62; 95% CI 0.43 to 0.90) and COVID-19 related 
death (aRR 0.17; 95% CI 0.07 to 0.98). Similar patterns 
of association were observed in different sensitivity 
analyses.
Conclusion Adults who engaged in the recommended 
levels of physical activity were associated with a 
decreased likelihood of SARS- CoV-2 infection, severe 
COVID-19 illness and COVID-19 related death. Our 
findings suggest that engaging in physical activity 
has substantial public health value and demonstrates 
potential benefits to combat COVID-19.
INTRODUCTION
The COVID-19 caused by the novel SARS- CoV-2 
has spread rapidly across the globe.1–3 Despite 
dedicated efforts to end the pandemic including 
vaccination and antiviral therapies based on blood 
products and antibody, the emergence of more than 
5000 mutations and the continued second or more 
waves of infection have made the prevailing situ-
ation extremely complicated.4 Baseline character-
istics of patients, including old age, obesity, heavy 
smoking status and underlying comorbidities, such 
as hypertension, respiratory disease, cardiovascular 
disease and cancer have been shown to be associated 
with increased risk of COVID-19 and COVID-19 
related death.1–3 5 6 There is rapidly accumulating 
evidence on the risk factors for COVID-19 that are 
a function of interactions between the pathogen, 
host and environment. However, there is limited 
information about the impact of an individual’s 
level of physical activity, an important modifiable 
factor, on the potential infectivity and prognosis of 
COVID-19.
Physical activity is one of the leading determi-
nants of health, and the lack of adequate physical 
activity is estimated to be responsible for 6%–10% 
of the global burden of major chronic diseases 
and 9% of premature deaths.7 Sufficient physical 
activity is known to be associated with substan-
tially reduced risk for all- cause and disease- specific 
mortality,8 multiple chronic diseases (such as meta-
bolic syndrome and type 2 diabetes),7 cancer7 and 
cardiovascular disease9 and improved physical func-
tion, cognition and quality of life.10 It is well estab-
lished that regular and sustained participation in 
physical activity is beneficial for almost every facet 
of health, and the supporting evidence continues to 
grow.10 Moreover, previous studies have suggested 
that physical activity has a protective effect against 
infectivity and severity of respiratory infection due 
to its immunological benefits.11–13 The recently 
published Physical Activity Guidelines for Ameri-
cans, second edition, which was originally proposed 
for preventing chronic disease- related mortality, 
provides a clear guidance on the types (such as 
aerobic and muscle- strengthening activity) and 
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amount (eg, 150–300 min a week of moderate intensity of phys-
ical activity for adults) of physical activity that provides substan-
tial health benefits.10
During the ongoing pandemic, measures taken by govern-
ments globally to control the transmission of COVID-19 include 
‘lock downs’ and social distancing.14–16 This has substantially 
decreased people’s daily behaviours, routine and population 
levels of physical activity,17 which may lead to an unhealthy 
lifestyle.10 Previous studies had investigated the potential asso-
ciation between physical activity and COVID-19 with inconsis-
tent results; no association with SARS- CoV-2 infectivity18 and 
COVID-19 severity,18 and beneficial association with COVID-19 
severity19–21 have been found by various studies. Thus, the 
impact of physical activity on COVID-19 infectivity and clinical 
outcomes remains unclear.
Previous studies had described the health benefits of physical 
activity including those on the immune system.22 We established 
the hypothesis that this association will also apply to COVID-19, 
an infectious respiratory disease. Therefore, the aim of this study 
was to investigate the hypothesis that sufficient physical activity 
may reduce the risk of COVID-19 infectivity, severity and its 
related mortality among patients who underwent SARS- CoV-2 
testing or decrease the length of hospital stay among patients 
confirmed with COVID-19. We used a large- scale, population- 
based, nationwide claim- based cohort data that included all 




We performed a high- quality, population- based, nationwide 
study using the data from the Korean National Health Insur-
ance Service (NHIS) that includes data of all individuals who 
underwent SARS- CoV-2 testing in South Korea through services 
facilitated by the Korea Disease Control and Prevention Agency 
(KDCA) and Ministry of Health and Welfare, South Korea, 
between 1 January 2020 and 30 May 2020. The following link 
can be used to access the Korean NHIS site: https://nhissnhi-
sorkr/bd/ab/bdaba000engdo/. The dataset links and consists of 
general health examination results, national COVID-19 related 
registers, including COVID-19 related outcomes and death 
records, and health insurance data for the past 5 years, including 
insurance eligibility data, outpatient and inpatient healthcare 
records, and pharmaceutical visits. The cohort dataset has the 
following characteristics: (1) the Korean government provided 
complimentary and mandatory health services and insurance 
to all Korean patients with COVID-191–3 5; (2) COVID-19 
related death and outcome records were obtained by national 
COVID-19 related registers generated by the KDCA; and (3) all 
patient- related data were anonymised to ensure confidentiality 
from the Korean government.
Study population
The study population comprised all Korean individuals aged 
≥20 years who underwent the SARS- CoV-2 testing between 1 
January 2020 and 15 May 2020 by medical or KDCA referral 
(excluding self- referral (self- referred patients were tested anon-
ymously for their privacy); n=212 768). Subsequently, we 
linked their national general health examination data between 1 
January 2018 and 31 December 2019 to obtain the assessment 
on their level of physical activity. If the participants had multiple 
health examination data, the most recent was used. The total 
observational period was from 1 January 2015 to 30 July 2020, 
and individual index data were the data of the first SARS- CoV-2 
testing for each patient. SARS- CoV-2 infection was confirmed 
by nasal and pharyngeal swabs using the laboratory real- time 
reverse transcriptase- PCR assay, which was authorised by the 
KDCA.1–3 5
Age, gender, household income and region of residence 
were obtained from insurance eligibility data. Smoking habits, 
frequency of alcohol consumption, physician- diagnosed history 
of diabetes mellitus, tuberculosis, stroke, cardiovascular disease, 
hypertension, dyslipidaemia and previous use of medication for 
hypertension, dyslipidaemia, diabetes mellitus and cardiovas-
cular disease were obtained from general health examination, 
including self- reported questionnaires and personal medical 
interview. Body mass index and systolic and diastolic blood pres-
sure were measured. Blood glucose and creatinine for estimating 
glomerular filtration rate and total cholesterol were obtained 
from fasting serum samples during general health examination. 
The Charlson comorbidity index was considered as reported 
previously.23
Exposures and outcomes
The leisure time physical activities of each participant was 
estimated during the general health examination and personal 
medical interview.23 Participants were asked to report the 
frequency of physical activity weekly in two categories: vigorous 
intensity physical activity is defined as intense exercise that 
causes severe shortness of breath (ie, running) and moderate 
intensity physical activity is defined as exercise that causes mild 
shortness of breath (such as brisk walking and bicycling). We 
calculated the time of physical activity in min/week by multi-
plying the frequency (times/week) and duration (min/time). 
Muscle strengthening was considered by frequency (times/week) 
using the following question according to physical activity guide-
lines10: ‘How often do you do muscle strengthening activities in 
a week, such as lifting weights or push- ups (times/week)’.
Aerobic physical activity was divided into two categories: 
recommended aerobic physical activity (≥150 min/week of 
moderate intensity activity or ≥75 min/week of vigorous 
intensity activity or greater than an equivalent combination) 
and insufficient aerobic physical activity (<150 min/week of 
moderate intensity activity, <75 min/week of vigorous inten-
sity activity and less than an equivalent combination). Equiva-
lent combination was calculated using the general rule that 2 
min of moderate- intensity activity counts the same as 1 min of 
vigorous intensity activity.10 Muscle strengthening activity was 
divided into two categories: recommended muscle strengthening 
activity (≥2 times/week) and insufficient muscle strengthening 
activity (<2 times/week). Using these categories for aerobic 
and muscle strengthening physical activity, the level of physical 
activity was categorised into four: (1) insufficient aerobic activity 
and muscle strengthening; (2) muscle strengthening only (insuf-
ficient aerobic activity and recommended muscle strengthening 
activity); (3) aerobic only (recommended aerobic activity and 
insufficient muscle strengthening activity); and (4) aerobic and 
muscle strengthening (both recommended activity).
In addition, we categorised physical activity according to 
metabolic equivalent task (MET) score on the energy cost. Each 
category of activity was assigned a MET score on the energy 
cost, and the weighted MET- minutes per week was calculated 
by multiplying the standard MET score, duration and frequency 
per week.24 25 Ratings of 4.0 and 8.0 METs were assigned for 
moderate and vigorous intensity activity, respectively.24 25 The 
level of physical activity was categorised into four: (1) inactive 
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(0 MET min/week), (2) insufficiently active (0–<500 MET min/
week), (3) active (500–<1000 MET min/week) and (4) highly 
active (more than 1000 MET min/week).
We linked the study participants to the national COVID-19 
related registers generated by KDCA. The outcomes examined 
were SARS- CoV-2 infection (positive laboratory SARS- CoV-2 
testing result), severe clinical outcomes of COVID-19 (ICU 
admission, administration of invasive ventilation or COVID-19 
related death),1–3 5 26 COVID-19 related death and/or length of 
hospital stay.
Eight cohorts studied
We generated the eight cohorts for robustness and generalisation 
of our results (online supplemental table S1 and figure 1): (1) 
cohort A was the main study that consisted of participants who 
received general health examination between 2018 and 2019 
(online supplemental figures S1 and S2; n=76 395); (2) propen-
sity score matched cohort A was performed by matching two 
groups (insufficient aerobic and muscle strengthening vs aerobic 
and muscle strengthening; n=5298); (3) cohort B consisted 
of only COVID-19 confirmed patients in cohort A (n=1293); 
(4) cohort C was conducted differential conditions of ‘expo-
sure’ using the MET score (online supplemental figures S3 and 
S4; n)=76 395); (5) propensity score matched cohort C was 
performed by matching two groups (insufficient physical activity 
group (0–500 MET min/week) vs sufficient physical activity 
group (more than 500 MET min/week); n=59 986); (6) cohort 
D consisted of participants who received general health exam-
ination between 2015 and 2019 (online supplemental figures 
S5 and S6; n=118 768); (7) propensity score matched cohort 
D was performed by matching two groups (insufficient physical 
activity group (0–500 MET min/week) vs sufficient physical 
activity group (more than 500 MET min/week); n=23 860); and 
(8) cohort E consisted of only COVID-19 confirmed patients in 
cohort C (n=3882).
Participants in cohort A and B were categorised by exercise 
guideline and those in cohort C by MET score.10 The Korean 
general health examination has added a questionnaire about 
muscle strengthening as of 2018; we could not calculate muscle 
strengthening by using data from 2015 to 2017. Therefore, 
participants in cohorts D and E were categorised by MET score. 
If the participants had multiple health examination data, the 
most recent was used.
Sample size calculation
Although there has been no study on the association between 
SARS- CoV-2 infectivity and physical activity, we calculated 
the sample size based on a previous study on the relationship 
between COVID-19 severity and physical activity.21 We had 
originally calculated that for each group to have an 80% power 
to show a 2.8- fold improvement of severity among COVID-19 
patients (1% in inactive group vs 2.8% in active group), at a 
5% significance level, we would need to enrol 900 patients with 
COVID-19 in each group. Finally, we included 1293 patients 
with COVID-19 who engaged in insufficient physical activity 
and 1002 patients with COVID-19 who engaged in sufficient 
muscle strengthening, aerobic or both physical activities.
Statistical analyses
In the nationwide Korean cohort, ‘exposure’ was the physical 
activities according to physical activity guidelines10 in cohorts 
A and B or those according to MET score in cohorts C–E. 
The ‘primary end point’ was the positive SARS- CoV-2 testing 
results, severe COVID-19 illness or COVID-19 related death in 
cohorts A–E; the ‘secondary endpoint’ was the length of hospital 
stay among COVID-19 confirmed patients in cohorts B and E. 
The ‘individual index data’ were the data of first laboratory 
SARS- CoV-2 testing.
To assess the different confounding effects in our study, we 
used three sequential inclusion adjusting model by modified 
Poisson regressions presented by adjusted relative risks (aRRs) 
with 95% CIs or multivariable analysis of covariance presented 
by adjusted mean difference with 95% CIs. We also fitted a 
Figure 1 Participant profile in all cohort.
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cubic spline model with four knots selected by the lowest Akaike 
information criterion.27 Furthermore, we confirmed the linearity 
assumption of systolic and diastolic blood pressure, fasting blood 
glucose and serum total cholesterol using Box- Tidwell test (all 
p value >0.05), the normality assumption of length of hospital 
stay using Kolmogorov- Smirnov test (p value >0.05) and homo-
geneity of variances assumption of length of hospital stay using 
Levene’s test (p value >0.05).
Model 1 was adjusted for age (20–39, 40–59 and ≥60 years) 
and sex. Model 2 was adjusted for age; sex; region of residence 
(Seoul Capital Area, Daegu/Gyeongbuk area and other area); 
Charlson comorbidity index (0, 1 and ≥2); history of diabetes 
mellitus, tuberculosis, stroke and cardiovascular disease; body 
mass index (continuous, using the cubic spline function); systolic 
blood pressure (continuous); diastolic blood pressure (contin-
uous); fasting blood glucose (continuous); serum total choles-
terol (continuous); glomerular filtration rate (≥90, 60–89 
and ≤59 mL/min); household income (low, middle and high); 
smoking (never, ex and current); alcoholic drinks (<1, 1–2, 
3–4 and ≥5 days per week); and medication for hypertension, 
diabetes mellitus and cardiovascular disease. Finally, model 3 was 
adjusted for minimal selected potential confounders by directed 
acyclic graph approach (figure 2; age, sex, region of residence, 
household income, smoking and alcoholic drinks).
To test the stability and reliability of our results, we performed 
several analyses with multiple conditions. First, we analysed two 
differential conditions of ‘exposure’ such as using the physical 
activity guidelines10 (cohorts A and B) and MET score (cohorts 
C–E). Second, we performed propensity score matching three 
times to reduce potential confounding effects and to balance the 
baseline characteristics (matched cohort A: insufficient aerobic 
and muscle strengthening vs aerobic and muscle strengthening; 
matched cohorts C and D: insufficient physical activity group 
vs sufficient physical activity group). Propensity scores were 
derived using a logistic regression model with adjustment (model 
2), and a ‘greedy nearest- neighbour’ algorithm was used to 
match patients in the two groups in a 1:1 ratio (random selection 
without participant replacement within specified calliper widths 
(0.01 SD)). We used robust SEs to obtain 95% CIs in matching 
analysis. Adequacy of matching was calculated by comparing 
standardised mean differences (SMDs) and propensity score 
density plot (online supplemental figures S7 and S9). An SMD 
of less than 0.1 indicates no major imbalance between the two 
groups.5 28 Third, we conducted the sensitivity analysis by gener-
ating cohorts B and E, including only patients with COVID-
19. Fourth, to avoid overfitting issues, a directed acyclic graph 
approach was used to confirm adequate potential mediators, and 
thus, a visualisation of the causal relationship between physical 
activity (‘exposure’) and the risk of COVID-19 (‘outcome’) was 
provided. Fifth, we performed the subgroup analysis, in which 
there was stratification according to age, gender, smoking status 
and Charlson comorbidity index, which have a statistical signifi-
cance of interaction (p interaction value <0.05). Finally, we used 
the Sidak’s correction for multiple comparisons to reduce the 
probability of type 1 error. Statistical analyses were performed 
using SPSS (V.25.0; IBM Corp, Armonk, New York, USA), R 
Figure 2 Directed acyclic graph demonstrating the implicitly assumed causal association between physical activity (‘exposure’) and risk of 
COVID-19 (‘outcome’) in the Korean nationwide cohort before matching. Confounders, potential mediators and exposure–outcome associations are 
indicated. BMI, body mass index; BP, blood pressure; CCI, Charlson comorbidity index; CVD, cardiovascular disease; GFR, glomerular filtration rate; TB, 
tuberculosis.
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software (V.3.1.1; R Foundation, Vienna, Austria) and SAS (V.9.4; 
SAS Institute).23 29 Directed acyclic graphs were presented using 
Daggity (V.2.3; http://www. dagitty. net/). A two- sided p value of 
less than 0.05 was considered statistically significant.
Patient and public involvement
No patients were directly involved in designing the research 
question or in conducting the research. No patients were asked 
for advice on interpretation or writing up of the results. There 
were no plans to involve patients or the relevant patient commu-
nity in the dissemination of study findings at this time.
RESULTS
Cohort A
Among 76 395 adults (age groups: 33.5% (20–39 years), 37.8% 
(40–59 years) and 28.7% (≥60 years); male, 48.8%), we identi-
fied 41 293 (54.1%), 5036 (6.6%), 18 994 (24.9%) and 11 072 
(14.5%) adults with insufficient aerobic and muscle strength-
ening, muscle strengthening only, aerobic only and aerobic and 
muscle strengthening, respectively (table 1). During the observa-
tion period, 2295 (3.0%), 446 (0.58%) and 45 (0.059%) adults 
were diagnosed with COVID-19 (SARS- CoV-2 test positive), 
severe COVID-19 and COVID-19 related death, respectively 
(online supplemental table S11).
Table 2 and figure 3 show that adults with aerobic and muscle 
strengthening had a lower risk of COVID-19 infection (3.1% 
for insufficient aerobic and muscle strengthening vs 2.6% for 
aerobic and muscle strengthening; aRR (model 2) 0.85; 95% CI 
0.72 to 0.98), severe COVID-19 (0.66% vs 0.35%; aRR (model 
2) 0.42; 95% CI 0.34 to 0.91) and COVID-19 related death 
(0.08% vs 0.02%; aRR (model 2) 0.23; 95% CI 0.06 to 0.99). In 
subgroup analysis stratified by the covariates (table 3), the effect 
sizes of risk of COVID-19 infection between patients with insuf-
ficient aerobic and muscle strengthening and those with aerobic 
and muscle strengthening were stronger among middle aged 
adults (40–59 years; aRR 0.85; 95% CI 0.70 to 0.99), men (aRR 
0.81; 95% CI 0.64 to 0.98), never smokers (aRR 0.79; 95% 
CI 0.58 to 0.94) and those having low Charlson comorbidity 
index (0 score; aRR 0.74; 95% CI 0.58 to 0.94) than in other 
groups. Similar effect sizes and patterns of severe COVID-19 
were found among older adults (≥60 years; aRR 0.16; 95% CI 
0.02 to 0.96), never smokers (aRR 0.44; 95% CI 0.23 to 0.99), 
and those having low Charlson comorbidity index (0 score; aRR 
0.23; 95% CI 0.09 to 0.80). Moreover, we also found similar 
patterns after Sidak’s correction (online supplemental table S12).
Matched cohort A
After 1:1 propensity score matching in cohort A (2649 for insuf-
ficient aerobic and muscle strengthening vs 2649 for aerobic and 
muscle strengthening), there were no major imbalances of base-
line characteristics assessed by SMDs (online supplemental table 
S2; all SMDs ≤0.04). Those with aerobic and muscle strength-
ening had 27% lower risk of COVID-19 (aRR (model 2) 0.73; 
95% CI 0.54 to 0.99) and 57% lower risk of severe COVID-19 
(aRR (model 2) 0.43; 95% CI 0.20 to 0.95) than those with 
insufficient aerobic and muscle strengthening (table 4).
Cohort B
Among COVID-19 confirmed patients in cohort A (table 4 and 
online supplemental table S2; n=2295), we found that those 
with aerobic and muscle strengthening had a decreased risk of 
severe COVID-19 (aRR (model 2) 0.66; 95% CI 0.47 to 0.90) 
and length of hospital stay (adjusted mean difference, −2.08 
days; 95% CI −4.04 to −0.14).
Cohort C
The 76 395 adults in cohort C were stratified according to MET 
score (table 4 and online supplemental table S4). The active 
group (500–<1000 MET min/week) was found to have 22% 
lower risk of COVID-19 infection (aRR (model 2) 0.78; 95% 
CI 0.66 to 0.92), 38% lower risk of severe COVID-19 (aRR 
(model 2) 0.62; 95% CI 0.43 to 0.90) and 83% lower risk of 
COVID-19- related death (aRR (model 2) 0.17; 95% CI 0.07 
to 0.98) than the inactive group. The insufficiently active group 
and highly active group had a modest 9% and 6% lower risk 
of COVID-19 infection, 22% and 21% lower risk of severe 
COVID-19 and 19% and 21% lower risk of COVID-19- related 
death than the inactive group, respectively (figure 3).
Matched cohort C
We conducted a propensity score matched analysis to compare 
low physical activity group (0 to 500 MET min/week) with 
sufficient physical activity group (≥500 MET min/week). There 
were no major imbalances in baseline characteristics assessed 
by SMDs (table 4 and online supplemental table S6; all SMDs 
<0.07). In model 2, there was less SARS- CoV-2 infection (aRR 
0.90; 95% CI 0.83 to 0.99) and severe COVID-19 (aOR 0.77; 
95% CI 0.63 to 0.95) in the high physical activity group than in 
the low physical activity group. Moreover, we also found similar 
patterns after Sidak’s correction (online supplemental table S13).
Cohort D
Among 118 768 included adults, we identified 22 811 (19.2%), 
50 052 (42.1%), 25 932 (21.8%) and 19 973 (16.8%) adults 
who were inactive, insufficiently active, active and highly active, 
respectively (online supplemental table S7). During the observa-
tion period, 3882 (3.3%), 277 (0.23%) and 122 (0.10%) adults 
were diagnosed with COVID-19 (SARS- CoV-2 test positive), 
severe COVID-19 and COVID-19 related death, respectively.
Online supplemental table S8 and figure 3 show that the 
active group (500–<1000 MET min/week) had 15% lower risk 
of COVID-19 infection (aRR (model 2) 0.85; 95% CI 0.75 to 
0.96), 46% lower risk of severe COVID-19 (aRR (model 2) 
0.54; 95% CI 0.35 to 0.79) and 65% lower risk of COVID-
19- related death (aRR (model 2) 0.35; 95% CI 0.20 to 0.64) 
than the inactive group. However, the insufficiently active group 
and highly active group had a modest 11% and 15% lower risk 
of COVID-19 infection, 35% and 34% lower risk of severe 
COVID-19 and 40% and 63% lower risk of COVID-19 related 
death than the inactive group, respectively (table 4).
Matched cohort D
We conducted a propensity score matched analysis to compare 
low physical activity group (0–500 MET min/week) with suffi-
cient physical activity group (≥500 MET min/week). There were 
no major imbalances in baseline characteristics assessed by SMDs 
(table 4 and online supplemental table S9; all SMDs <0.015). In 
model 2, there was less SARS- CoV-2 infection (aRR 0.87; 95% 
CI 0.76 to 0.99), severe COVID-19 (aOR 0.58; 95% CI 0.35 
to 0.99) and COVID-19 related mortality (aOR 0.46; 95% CI 
0.22 to 0.96) in the high physical activity group than in the low 
physical activity group.
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Table 1 Baseline characteristics of patients who performed the SARS- CoV-2 testing in the Korean nationwide cohort (cohort A)
Characteristic Entire cohort






Aerobic and muscle 
strengthening
Total, n (%) 76 395 (100.0) 41 293 (54.1) 5036 (6.6) 18 994 (24.9) 11 072 (14.5)
Age, years, n (%)
  20–39 25 614 (33.5) 13 005 (31.5) 1747 (34.7) 6072 (32.0) 4790 (43.3)
  40–59 28 856 (37.8) 15 677 (38.0) 2028 (40.3) 7091 (37.3) 4060 (36.7)
  ≥60 21 925 (28.7) 12 611 (30.5) 1261 (25.0) 5831 (30.7) 2222 (20.1)
Sex, n (%)
  Male 37 272 (48.8) 17 703 (42.9) 3156 (62.7) 9217 (48.5) 7196 (65.0)
  Female 39 123 (51.2) 23 590 (57.1) 1880 (37.3) 9777 (51.5) 3876 (35.0)
Region of residence, n (%)
  Seoul Capital rea 34 149 (44.7) 18 442 (44.7) 2448 (48.6) 8200 (43.2) 5059 (45.7)
  Daegu/Gyeongbuk area 14 910 (19.5) 8203 (19.8) 1034 (20.5) 3704 (19.5) 1969 (17.8)
  Other area 27 336 (35.8) 14 648 (35.5) 1554 (30.9) 7090 (37.3) 4044 (36.5)
Charlson comorbidity index, n (%)
  0 44 854 (58.7) 23 405 (56.7) 3137 (62.3) 10 971 (57.8) 7341 (66.3)
  1 9361 (12.3) 5234 (12.7) 617 (12.3) 2277 (12.0) 1233 (11.1)
  ≥2 22 180 (29.0) 12 654 (30.6) 1282 (25.5) 5746 (30.3) 2498 (22.6)
History of diabetes mellitus, n (%) 6518 (8.5) 3738 (9.1) 355 (7.1) 1745 (9.2) 680 (6.1)
History of tuberculosis, n (%) 1585 (2.1) 860 (2.1) 121 (2.4) 383 (2.0) 221 (2.0)
History of stroke, n (%) 1038 (1.4) 640 (1.6) 45 (0.9) 261 (1.4) 92 (0.8)
History of cardiovascular disease, n (%) 2357 (3.1) 1372 (3.3) 151 (3.0) 601 (3.2) 233 (2.1)
History of hypertension, n (%) 14 528 (19.0) 8245 (20.0) 832 (16.5) 3866 (20.4) 1585 (14.3)
History of dyslipidaemia, n (%) 5355 (7.0) 2988 (7.2) 336 (6.7) 1425 (7.5) 606 (5.5)
Body mass index, kg/m2, n (%)
  Mean (SD) 23.9 (3.8) 23.8 (3.9) 23.7 (3.3) 24.1 (3.8) 24.1 (3.5)
  <25 49 286 (64.5) 26 883 (65.1) 3398 (67.5) 11 881 (62.6) 7124 (64.3)
  25–30 22 453 (29.4) 11 822 (28.6) 1442 (28.6) 5822 (30.7) 3367 (30.4)
  ≥30 4656 (6.1) 2588 (6.3) 196 (3.9) 1291 (6.8) 581 (5.3)
Systolic blood pressure, mm Hg, mean (SD) 121.2 (14.8) 121.2 (15.2) 121.1 (14.4) 121.6 (13.6) 120.8 (13.7)
Diastolic blood pressure, mm Hg, mean (SD) 74.9 (10.0) 74.8 (10.1) 74.9 (9.9) 75.0 (9.9) 74.8 (9.7)
Fasting blood glucose, mg/dL, mean (SD) 99.4 (24.7) 99.8 (25.9) 97.9 (21.3) 99.8 (24.3) 98.2 (22.0)
Serum total cholesterol, mg/dL, mean (SD) 191.4 (40.4) 191.7 (41.5) 191.9 (38.4) 190.5 (39.6) 191.4 (38.4)
Glomerular filtration rate, mL/min, n (%)
  ≥90 40 449 (52.9) 22 168 (53.9) 26 665 (53.1) 9807 (51.9) 5809 (52.7)
  60–89 31 051 (40.6) 16 026 (39.0) 2110 (42.0) 8065 (42.7) 4850 (44.0)
  ≤59 4580 (6.0) 2923 (7.1) 247 (4.9) 1035 (5.5) 375 (3.4)
Household income, n (%)
  Low (0–39 percentile) 21 427 (28.4) 12 186 (29.5) 1175 (23.3) 5339 (28.1) 2727 (24.6)
  Middle (40–79 percentile) 33 482 (43.8) 17 927 (43.4) 2216 (44.0) 8361 (44.0) 4978 (45.0)
  High (80–100 percentile) 21 486 (28.1) 11 180 (27.1) 1645 (32.7) 5294 (27.9) 3367 (30.4)
Smoking, n (%)
  Never smoker 50 227 (65.7) 28 472 (69.0) 2931 (58.2) 12 442 (65.6) 6382 (57.6)
  Ex- smoker 12 492 (16.4) 5691 (13.8) 1171 (23.3) 3170 (16.7) 2460 (22.2)
  Current smoker 13 676 (17.9) 7130 (17.3) 934 (18.6) 3382 (17.8) 2230 (20.1)
Alcoholic drinks, days per week, n (%)
  <1 47 769 (62.5) 27 003 (65.5) 2843 (56.5) 11 839 (62.5) 6084 (55.0)
  1–2 20 375 (26.7) 9988 (24.2) 1598 (31.8) 5044 (26.6) 3745 (33.9)
  3–4 6074 (8.0) 3103 (7.5) 470 (9.3) 1542 (8.1) 959 (8.7)
  ≥5 2075 (2.7) 1154 (2.8) 120 (2.4) 534 (2.8) 267 (2.4)
Use of medication, n (%)
  Medication for hypertension, n (%) 13 663 (17.9) 7775 (18.8) 774 (15.4) 3659 (19.3) 1455 (13.1)
  Medication for dyslipidaemia, n (%) 4450 (5.8) 2494 (6.0) 264 (5.2) 1206 (6.4) 486 (4.4)
  Medication for diabetes mellitus, n (%) 6080 (8.0) 3494 (8.5) 325 (6.5) 1635 (8.6) 626 (5.7)
  Medication for cardiovascular disease, n (%) 2153 (2.8) 1252 (3.0) 134 (2.7) 555 (2.9) 212 (1.9)
SD, standard deviation.
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Cohort E
Among the patients diagnosed with COVID-19 (n=3882), the 
risk of severe COVID-19 was less in the insufficiently active 
group (aRR (model 2) 0.73; 95% CI 0.53 to 0.99) and active 
group (aRR (model 2) 0.68; 95% CI 0.44 to 0.98) than in the 
inactive group. The COVID-19 related mortality among patients 
with COVID-19 was lower in the active group (aRR (model 
2) 0.49; 95% CI 0.27 to 0.82) and highly active group (aRR 
(model 2) 0.43; 95% CI 0.22 to 0.83) than in the inactive group 
(table 4 and online supplemental table S10). The length of stay in 
hospital of patients with COVID-19 was lower only in the active 
group (adjusted mean difference, −1.85 day; 95% CI −3.63 to 
−0.05) than the inactive group, while no further benefits were 
observed in the insufficiently and highly active groups.
DISCUSSION
Findings of our study
To our knowledge, this is the first large- scale, population- based, 
nationwide study that investigated the relationship of physical 
activity with the infectivity and severity of COVID-19 and its 
related death. In this nationally representative cohort study, we 
found that those who reported aerobic and muscle strengthening 
activities that met or exceeded the 2018 exercise guidelines had 
a lower risk of SARS- CoV-2 infection (aRR 0.85; 95% CI 0.72 
to 0.96), severe COVID-19 illness (aRR 0.42; 95% CI 0.19 to 
0.91) and COVID-19 related death (aRR 0.24; 95% CI 0.05 to 
0.99) than those who did not. The effect sizes of these associ-
ations were significant among the elderly, men, never smokers 
and those having low Charlson comorbidity index. Furthermore, 
the recommended key target range of MET score (500–1000 
MET min/week) was associated with the maximum beneficial 
effect size for the reduced risk of SARS- CoV-2 infection (aRR 
0.78; 95% CI 0.66 to 0.92), severe COVID-19 illness (aRR 
0.62; 95% CI 0.43 to 0.90) and COVID-19 related death 
(aRR 0.17; 95% CI 0.07 to 0.98). Interestingly, the length of 
stay in hospital was shortened about approximately 2 days in 
patients who performed both aerobics and muscle strengthening 
(adjusted mean difference: −2.08 days) or with MET 500–1000 
MET min/week (adjusted mean difference: −1.85 days). These 
findings were consistent across a broad range of sensitivity 
and subgroup analyses using cohorts A–E or propensity score 
matching.
Comparison with previous studies
While several studies describe the health benefits of physical 
activity, most studies focused on non- communicable diseases.8 
Few studies on physical activity and risk of respiratory infec-
tious diseases have shown inconsistent results: beneficial asso-
ciation in USA (n=78 062)11 and Poland (n=1028)13 and no 
association in Denmark (n=5368),30 Sweden (n=2038)31 and 
USA (n=83 165).32 Furthermore, several intervention trials 
conducted in the USA, Brazil, Canada, Portugal, Spain and 
Turkey have produced non- conclusive and inconsistent results.33 
Small sample size, heterogeneity of the study population, short- 
term follow- up period and inappropriate study design (ie, cross- 
sectional or uncontrolled cohort design) contributed to low 
levels of evidence and inconsistent results.11 13 30–33 However, 
a recent meta- analysis of 14 intervention trials suggested that 
exercise had a significant effect on the severity of symptoms and 
number of symptom days (mean difference −2.24 days), similar 
to our results. Moreover, a recent large meta- analysis including 
55 studies suggested that physical activity is associated with a 
Table 2 Adjusted relative risk (95% CIs) of SARS- CoV-2 infection, severe COVID-19 outcomes and COVID-19 related deaths associated with study 
patients who engaged in physical activities according to exercise guideline (cohort A)
Event
Types of physical activity
Insufficient aerobic and 
muscle strengthening Muscle strengthening only Aerobic only
Aerobic and muscle 
strengthening
COVID-19, n (%) 1293/41 293 (3.1) 150/5036 (3.0) 561/18 994 (3.0) 291/11 072 (2.6)
  Adjusted RR (95% CI)
  Model 1* (age and sex adjusted) 1.0 (ref) 1.08 (0.91 to 1.29) 0.98 (0.88 to 1.09) 0.87 (0.75 to 0.98)
  Model 2† (fully adjusted) 1.0 (ref) 1.01 (0.73 to 1.42) 0.92 (0.77 to 1.12) 0.84 (0.73 to 0.96)
  Model 3‡ (selected confounders by DAGs) 1.0 (ref) 1.03 (0.86 to 1.22) 0.97 (0.88 to 1.07) 0.85 (0.72 to 0.98)
Severe COVID-19§, n (%) 273/41 293 (0.66) 25/5036 (0.50) 109/18 994 (0.57) 39/11 072 (0.35)
  Adjusted RR (95% CI)
  Model 1* (age and sex adjusted) 1.0 (ref) 0.85 (0.56 to 1.29) 0.87 (0.70 to 1.09) 0.59 (0.39 to 0.87)
  Model 2† (fully adjusted) 1.0 (ref) 0.93 (0.61 to 1.42) 0.86 (0.69 to 1.08) 0.42 (0.19 to 0.91)
  Model 3‡ (selected confounders by DAGs) 1.0 (ref) 0.88 (0.58 to 1.33) 0.86 (0.69 to 1.08) 0.56 (0.34 to 0.88)
COVID-19 related death, n (%) 32/41 293 (0.08) 0/5036 (0.00) 11/18 994 (0.06) 2/11 072 (0.02)
  Adjusted RR (95% CI)
  Model 1* (age and sex adjusted) 1.0 (ref) NA 0.70 (0.35 to 1.41) 0.23 (0.06 to 0.98)
  Model 2† (fully adjusted) 1.0 (ref) NA 0.71 (0.34 to 1.41) 0.26 (0.07 to 0.99)
  Model 3‡ (selected confounders by DAGs) 1.0 (ref) NA 0.71 (0.34 to 1.40) A0.24 (0.06 to 0.99)
Numbers in bold indicate significant differences (p<0.05).
*Model 1: adjusted for age (20–39, 40–59 and ≥60 years) and sex.
†Model 2: adjusted for the age; sex; region of residence (Seoul Capital Area, Daegu/Gyeongbuk area and other areas); Charlson comorbidity index (0, 1 and ≥2); history of 
diabetes mellitus, tuberculosis, stroke and cardiovascular disease; body mass index (continuous; using the cubic spline function); systolic blood pressure (continuous; using the 
restricted cubic spline function); diastolic blood pressure (continuous); fasting blood glucose (continuous); serum total cholesterol (continuous); glomerular filtration rate (≥90, 
60–89 and ≤59 mL/min); household income (low, middle and high); smoking (never, ex and current); alcoholic drinks (<1, 1–2, 3–4 and ≥5 days per week); and medication for 
hypertension, diabetes mellitus and cardiovascular disease.
‡Model 3: adjusted for potential confounders selected by DAGs (age; sex; region of residence; household income; smoking; and alcoholic drinks).
§Severe COVID-19 consisted of requirement of oxygen therapy, admission to the intensive care unit, invasive ventilation or death.
DAGs, directed acyclic graphs; RR, relative risk.
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31% and 37% risk reduction of community acquired infectious 
disease and its related mortality, respectively, which is consistent 
with our results.12
Though there are previous studies on the association between 
physical activity and the risk of COVID-19, the results are incon-
sistent; no association of physical activity with SARS- CoV-2 
infectivity18 and COVID-19 severity18; and beneficial associa-
tion with COVID-19 severity.19–21 Small sample size (patients 
with COVID-19, n=20718 or 246),19 uncontrolled cohort 
design,18–21 non- various definitions of physical activity,18–21 non- 
sophisticated statistical techniques to reduce several biases18–21 
and different methods of collecting data for measuring exer-
cise (24- hour movement patterns and self- reported question-
naire) contributed to inconsistent results in these studies (online 
supplemental table S14). Furthermore, most of the studies were 
conducted in the UK and USA18–21; the findings in Asia were 
unknown. These studies had explained the association using the 
hypothesis that regular physical activity is an important contrib-
utor to exercise capacity and favourably influences biological 
pathways that are involved with the body’s response to an infec-
tion, which is a consistent hypothesis supporting our results. 
Moreover, our study was primarily demonstrated the benefi-
cial relationship between SARS- CoV-2 infectivity and physical 
activity.
Possible explanations of our results
Habitual exercise has the following beneficial effect on the 
immune system34: (1) enhanced immunosurveillance with an 
immune defence activity and metabolic health by increased 
immunoglobulins, anti- inflammatory cytokines (interleukin 
(IL)-6, IL- 1ra and IL-10), neutrophils, cytotoxic T, immature B 
and natural killer cell subsets; (2) reduced systemic inflammation 
promoted by the recirculation of immune cells and mediates an 
anti- inflammatory and antioxidant state through multiple path-
ways; and (3) improved regulation of the immune system and 
delayed onset of immunosenescence. In addition, a previous 
study demonstrated that physical activity inhibits lung inflamma-
tion and bacterial colonisation in respiratory infectious disease 
involving IL-10/nuclear factor-κB.35 Recently, a study reported 
that physical activity helps to shift the balance of the ACE2 
axis.36 It means that physical activity induces expression of 
ACE2 in skeletal muscle that leads to reduced circulating ACE2 
that may have protective effect in susceptibility to SARS- CoV-2 
and severity of COVID-19.36 The above- mentioned immunolog-
ical benefits of exercise may prevent the infection, severity and 
death due to COVID-19.
Policy implication
Recent studies reported that total physical activity signifi-
cantly decreased between immediately before and during the 
COVID-19 pandemic worldwide and across all age groups.17 
Although research evidence continues to mount that decreased 
in physical activity during the COVID-19 pandemic is a crit-
ical threat to public health, its impact on infectivity and clinical 
outcomes has not been clearly defined. The results of this study 
demonstrated the importance of physical activity in decreasing 
the risk of infectivity, severity and mortality of COVID-19, so 
that it can be reflected in future guidelines. The WHO launched 
‘#HealthAtHome’ campaign, including the recommendation 
of physical activity, to help manage weight and reduce the risk 
of non- communicable diseases such as cardiometabolic disease 
that can increase susceptibility to or severity of COVID-19.37 38 
WHO recommended that people of all ages and abilities need 
to be as active as possible and encouraged people to engage in 
regular aerobic physical activity and bone and muscle strength-
ening activity.37
Figure 3 Association between physical activity according to 2018 
physical activity guidelines for Americans and SARS- CoV-2 infection, 
severe COVID-19 illness and COVID-19 related death in cohort A. (A) 
Association between physical activity according to MET score and 
SARS- CoV-2 infection, severe COVID-19 illness and COVID-19 related 
death in cohort C (B) and cohort D (C). The level of physical activity was 
categorised into four: (1) inactive (0 MET min/week), (2) insufficiently 
active (0–<500 MET min/week), (3) active (500–<1000 MET min/
week) and (4) highly active (more than 1000 MET min/week). Whiskers 
represent 95% CIs, and dots indicate full adjusted relative risks. MET, 
metabolic equivalent of task.
9Lee SW, et al. Br J Sports Med 2021;0:1–13. doi:10.1136/bjsports-2021-104203
Original research
Strengths and limitations
There are several limitations in this study that need to be 
addressed. First, physical activity was assessed by self- report, 
which may lead to misclassification. Misclassification of phys-
ical activities by a self- report usually leads to regression dilution 
bias, which may lead to an underestimation of the magnitude of 
true association.22 Second, we can only assess the binary variable 
of muscle strengthening activity. Although frequency of muscle 
strengthening activity was not available, 2018 physical activity 
guidelines recommend only the use of binary variable (≥2 times/
week), not frequency data. Third, the data of physical activity 
status was obtained at a single point of recent general health 
examinations and excluded light intensity physical activity. 
Furthermore, there is the possibility that individuals may tend 
to overestimate levels of physical activity on average with varia-
tions in possible effects, especially over longer periods of recall. 
However, the ‘exposure’ of physical activity can change at index 
data, which may influence the magnitude of the true association. 
Moreover, physical activity was only collected during leisure 
time; household and occupation- related physical activities were 
missing, which may influence the magnitude of true associa-
tion.39 Future prospective cohort or interventional studies with 
serial and direct measurements of physical activity (ie, mobile 
exercise apps) are needed to investigate the true association 
between exercise and COVID-19. Fourth, although we adjusted 
a variety of covariates and matched using propensity score, we 
cannot exclude the possibility of unexpected confounding vari-
ables such as dietary patterns. To address this, we generated 
several cohort studies and performed several sensitivity anal-
yses that may make our results robust and generalisable. Fifth, 
our results should be interpreted with caution since our study 
comprised only Asian patients (Korean), and ethnic prevalence 
of ACE2 polymorphism is different, which may affect the ACE2 
axis. Finally, COVID-19 outcomes have improved over time, due 
Table 3 Subgroup analysis of the association of SARS- CoV-2 infection and severe COVID-19 outcomes associated with study patients who 
engaged in physical activities according to exercise guideline
Subgroups Event
Types of physical activity
Insufficient aerobic and 
muscle strengthening Muscle strengthening only Aerobic only
Aerobic and muscle 
strengthening
Age groups (years)   
  20–39 COVID-19 1.0 (ref) 1.43 (0.63 to 3.17) 1.13 (0.55 to 2.27) 0.99 (0.51 to 1.99)
  40–59 COVID-19 1.0 (ref) 1.04 (0.66 to 1.64) 0.98 (0.76 to 1.27) 0.85 (0.70 to 0.99)
  ≥60 COVID-19 1.0 (ref) 0.83 (0.44 to 1.52) 0.82 (0.61 to 1.10) 0.77 (0.51 to 1.19)
Sex   
  Male COVID-19 1.0 (ref) 1.02 (0.67 to 1.54) 0.97 (0.73 to 1.29) 0.81 (0.64 to 0.98)
  Female COVID-19 1.0 (ref) 1.06 (0.62 to 1.79) 0.90 (0.71 to 1.15) 0.90 (0.66 to 1.28)
Smoking   
  Never smoker COVID-19 1.0 (ref) 1.02 (0.67 to 1.54) 0.97 (0.73 to 1.29) 0.79 (0.64 to 0.99)
  Ex- smoker COVID-19 1.0 (ref) 0.91 (0.45 to 1.84) 0.92 (0.57 to 1.51) 0.75 (0.45 to 1.31)
  Current smoker COVID-19 1.0 (ref) 0.90 (0.27 to 2.93) 1.28 (0.64 to 2.48) 1.33 (0.58 to 3.00)
Charlson comorbidity index   
  0 COVID-19 1.0 (ref) 1.09 (0.72 to 1.61) 0.99 (0.78 to 1.30) 0.74 (0.58 to 0.94)
  1 COVID-19 1.0 (ref) 0.83 (0.34 to 2.03) 1.16 (0.74 to 1.79) 0.53 (0.16 to 1.09)
  ≥2 COVID-19 1.0 (ref) 0.95 (0.54 to 1.11) 0.78 (0.54 to 1.12) 1.48 (0.94 to 2.31)
Age groups (years)   
  20–39 Severe COVID-19† 1.0 (ref) 1.03 (0.62 to 1.76) 0.66 (0.50 to 1.05) 0.58 (0.25 to 1.30)
  40–59 Severe COVID-19† 1.0 (ref) 1.09 (0.61 to 2.02) 0.67 (0.43 to 1.19) 0.48 (0.15 to 1.24)
  ≥60 Severe COVID-19† 1.0 (ref) 0.79 (0.26 to 3.05) 0.58 (0.18 to 1.75) 0.16 (0.02 to 0.96)
Sex   
  Male Severe COVID-19† 1.0 (ref) 0.97 (0.60 to 1.60) 0.79 (0.56 to 1.27) 0.45 (0.18 to 1.07)
  Female Severe COVID-19† 1.0 (ref) 1.14 (0.64 to 2.09) 0.57 (0.41 to 0.95) 0.48 (0.15 to 1.26)
Smoking   
  Never smoker Severe COVID-19† 1.0 (ref) 1.25 (0.81 to 1.96) 0.59 (0.45 to 0.94) 0.44 (0.23 to 0.99)
  Ex- smoker Severe COVID-19† 1.0 (ref) 0.67 (0.32 to 1.56) 0.81 (0.46 to 1.55) 0.54 (0.14 to 1.45)
  Current smoker Severe COVID-19† 1.0 (ref) 0.60 (0.17 to 3.85) 1.19 (0.48 to 2.94) 0.28 (0.06 to 2.15)
Charlson comorbidity index   
  0 Severe COVID-19† 1.0 (ref) 0.89 (0.51 to 1.63) 0.52 (0.33 to 0.96) 0.23 (0.09 to 0.80)
  1 Severe COVID-19† 1.0 (ref) 1.00 (0.41 to 2.65) 0.56 (0.26 to 1.27) 0.81 (0.31 to 2.41)
  ≥2 Severe COVID-19† 1.0 (ref) 1.09 (0.63 to 1.95) 0.81 (0.59 to 1.28) 0.57 (0.32 to 1.34)
Numbers in bold indicate significant differences (p<0.05).
Values are adjusted relative risks* (95% CIs; cohort A).
*Regression models were adjusted for age (20–39, 40–59 and ≥60 years); sex; region of residence (Seoul Capital Area, Daegu/Gyeongbuk area, and other area); Charlson 
comorbidity index (0, 1 and ≥2); history of diabetes mellitus, tuberculosis, stroke and cardiovascular disease; body mass index (continuous; using the restricted cubic spline 
function); systolic blood pressure (continuous); diastolic blood pressure (continuous); fasting blood glucose (continuous); serum total cholesterol (continuous); glomerular 
filtration rate (≥90, 60–89 and ≤59 mL/min); household income (low, middle and high); smoking (never, ex and current); alcoholic drinks (<1, 1–2, 3–4 and ≥5 days per week); 
medication for hypertension, diabetes mellitus and cardiovascular disease.
†Severe COVID-19 consisted of requirement of oxygen therapy, admission to the intensive care unit, invasive ventilation or death.
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Table 4 Sensitivity and additional analysis of the association of SARS- CoV-2 infection, severe COVID-19 outcomes and COVID-19 related death 
associated with study patients who engaged in physical activities according to exercise guideline or MET score
Events Cohort N (%) Exposure Adjusted RR (95% CI)
COVID-19 Online supplemental table S2; Propensity 
score matched cohort A
95/2649 (3.6) Insufficient aerobic and muscle strengthening 1.0 (ref)*
    69/2649 (2.6) Aerobic and muscle strengthening 0.73 (0.54 to 0.99)
COVID-19 Online supplemental table S5; cohort C 1087/33 263 (3.3) Inactive (MET, 0) 1.0 (ref)†
    344/12 650 (2.7) Insufficiently active (MET, 1–<500) 0.91 (0.79 to 1.04)
    249/9689 (2.6) Active (MET, 500–<1000) 0.78 (0.66 to 0.92)
    615/20 793 (3.0) Highly active (MET, ≥1000) 0.94 (0.85 to 1.05)
COVID-19 Online supplemental table S6; Propensity 
score matched cohort C
991/29 993 (3.3) Low physical activity (MET, 0–500) 1.0 (ref)†
    852/29 993 (2.8) High physical activity (MET, ≥500) 0.90 (0.83 to 0.99)
COVID-19 Online supplemental table S8; cohort D 803/22 811 (3.5) Inactive (MET, 0) 1.0 (ref)†
    1641/50 052 (3.3) Insufficiently active (MET, 1–<500) 0.89 (0.82 to 0.97)
    816/25 932 (3.2) Active (MET, 500–<1000) 0.85 (0.75 to 0.96)
    622/19 973 (3.1) Highly active (MET, ≥1000) 0.85 (0.74 to 0.99)
COVID-19 Online supplemental table S9; propensity 
score matched cohort D
429/11 930 (3.6) Low physical activity (MET, 0–500) 1.0 (ref)†
    372/11 930 (3.1) High physical activity (MET, ≥500) 0.87 (0.76 to 0.99)
Severe COVID-19‡ Online supplemental table S2; propensity 
score matched cohort A
21/2649 (0.79) Insufficient aerobic and muscle strengthening 1.0 (ref)*
    9/2649 (0.34) Aerobic and muscle strengthening 0.43 (0.20 to 0.95)
Severe COVID-19‡ Online supplemental table S3; cohort B 273/1293 (21.1) Insufficient aerobic and muscle strengthening 1.0 (ref)*
    25/150 (16.7) Muscle strengthening only 0.87 (0.58 to 1.26)
    109/561 (19.4) Aerobic only 0.90 (0.72 to 1.10)
    39/291 (13.4) Aerobic and muscle strengthening 0.66 (0.47 to 0.90)
Severe COVID-19‡ Online supplemental table S5; cohort C 239/33 263 (0.72) Inactive (MET, 0) 1.0 (ref)†
    58/12 650 (0.46) Insufficiently active (MET, 1–<500) 0.78 (0.53 to 1.12)
    39/9689 (0.40) Active (MET, 500–<1000) 0.62 (0.43 to 0.90)
    110/20 793 (0.53) Highly active (MET, ≥1000) 0.79 (0.61 to 1.03)
Severe COVID-19‡ Online supplemental table S6; propensity 
score matched cohort C
209/29 993 (0.70) Low physical activity (MET, 0–500) 1.0 (ref)†
    146/29 993 (0.49) High physical activity (MET, ≥500) 0.77 (0.63 to 0.95)
Severe COVID-19‡ Online supplemental table S8; cohort D 75/22 811 (0.33) Inactive (MET, 0) 1.0 (ref)†
    109/50 052 (0.22) Insufficiently active (MET, 1–<500) 0.65 (0.47 to 0.86)
    49/25 932 (0.19) Active (MET, 500–<1000) 0.54 (0.35 to 0.79)
    44/19 973 (0.22) Highly active (MET, ≥1000) 0.66 (0.45 to 0.96)
Severe COVID-19‡ Online supplemental table S9; propensity 
score matched cohort D
40/11 930 (0.28) Low physical activity (MET, 0–500) 1.0 (ref)†
    24/11 930 (0.20) High physical activity (MET, ≥500) 0.58 (0.35 to 0.99)
Severe COVID-19‡ Online supplemental table S10; cohort E 75/803 (9.3) Inactive (MET, 0) 1.0 (ref)†
    109/1641 (6.6) Insufficiently active (MET, 1–<500) 0.73 (0.53 to 0.99)
    49/816 (6.0) Active (MET, 500–<1000) 0.68 (0.44 to 0.98)
    44/622 (7.1) Highly active (MET, ≥1000) 0.74 (0.48 to 1.12)
COVID-19 related 
death
Online supplemental table S2; propensity 
score matched cohort A
3/2649 (0.11) Insufficient aerobic and muscle strengthening 1.0 (ref)*
    1/2619 (0.04) Aerobic and muscle strengthening 0.34 (0.04 to 3.20)
COVID-19 related 
death
Online supplemental table S3; cohort B 32/1293 (205) Insufficient aerobic and muscle strengthening 1.0 (ref)*
    0/150 (0.0) Muscle strengthening only NA
    11/561 (2.0) Aerobic only 0.71 (0.35 to 1.42)
    2/291 (0.7) Aerobic and muscle strengthening 0.28 (0.06 to 1.20)
COVID-19 related 
death
Online supplemental table S5; cohort C 27/33 263 (0.07) Inactive (MET, 0) 1.0 (ref)†
    5/12 650 (0.05) Insufficiently active (MET, 1–<500) 0.81 (0.22 to 2.42)
    1/9689 (0.01) Active (MET, 500–<1000) 0.17 (0.07 to 0.98)
    12/20 793 (0.06) Highly active (MET, ≥1000) 0.79 (0.42 to 1.59)
COVID-19 related 
death
Online supplemental table S6; propensity 
score matched cohort C
23/29 993 (0.07) Low physical activity (MET, 0–500) 1.0 (ref)†
Continued
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to improvement in management,40 and our study was performed 
with data from the early stages of the pandemic. Further longi-
tudinal studies are warranted. Sixth, measurement error in some 
confounders such as alcohol consumption and household income 
can result in residual confounding. Furthermore, the estimates 
are biased as the study did not capture the time- varying nature 
of both exposure and many of the confounders.41 Seventh, some 
estimated 95% CIs such as 0.05 or 0.06 in table 2 clearly suggest 
sparse data bias, which should be acknowledged as an important 
limitation.42 Although we used several analyses such as modified 
Poisson regressions model and matching analysis, it should be 
noted that the target effect of each analysis are different. While 
conditional effect is estimated in modified Poisson regressions, 
average effect in the exposed group is estimated in propensity 
score methods. Finally, patients with self- referral were tested 
anonymously to maintain privacy, and their data were unavail-
able in our database; therefore, exclusion of those with self- 
referral may have led to increase in selection bias.
Despite these limitations, this is the first large- scale, 
population- based, nationwide study to investigate the associa-
tion between physical activity and risk of COVID-19 infectivity, 
severity and related death. Our data were collected from a large 
population that contains nationwide data of physical activity of 
over 100 000 individuals. To date, this is the first and largest 
analysis that focused on these relationships. We used the vali-
dated physical activity assessment according to the 2018 physical 
activity guidelines for Americans, and our data (such as previous 
medical history, body mass index, blood pressure and blood 
sample) were measured or obtained by medical staff during 
personal medical interview.
CONCLUSIONS
This study provides new evidence that physical activity, including 
both aerobic and muscle strengthening exercises, led to substan-
tial reductions in the infectivity of SARS- CoV-2, risk of poor 
outcomes and death related to COVID-19. In particular, the 
effect sizes of these associations were significant among elderly, 
men, never smokers and those having low Charlson comorbidity 
index. However, the recommended key target range of MET 
score was associated with the maximum beneficial effect size for 
reduced the risk of SARS- CoV-2 infection, severe COVID-19 
Events Cohort N (%) Exposure Adjusted RR (95% CI)
    11/29 993 (0.04) High physical activity (MET, ≥500) 0.51 (0.26 to 1.01)
COVID-19 related 
death
Online supplemental table S8; cohort D 39/22 811 (0.17) Inactive (MET, 0) 1.0 (ref)†
    53/50 052 (0.11) Insufficiently active (MET, 1–<500) 0.60 (0.40 to 0.93)
    17/25 932 (0.07) Active (MET, 500–<1000) 0.35 (0.20 to 0.64)
    13/19 973 (0.07) Highly active (MET, ≥1000) 0.37 (0.19 to 0.71)
COVID-19 related 
death
Online supplemental table S9; propensity 
score matched cohort D
21/11 930 (0.18) Low physical activity (MET, 0–500) 1.0 (ref)‡
    9/11 930 (0.08) High physical activity (MET, ≥500) 0.46 (0.22 to 0.96)
COVID-19 related 
death
Online supplemental table S10; cohort E 39/803 (4.9) Inactive (MET, 0) 1.0 (ref)†
    53/1641 (3.2) Insufficiently active (MET, 1–<500) 0.74 (0.49 to 1.06)
    17/816 (2.1) Active (MET, 500–<1000) 0.49 (0.27 to 0.82)
    13/622 (2.1) Highly active (MET, ≥1000) 0.43 (0.22 to 0.83)
Events Cohort Mean day (SD) Exposure Adjusted mean difference* 
(95% CI)
Length of stay in 
hospital
Online supplemental table S3; cohort B 27.4 (15.3) Insufficient aerobic and muscle strengthening 1.0 (ref)*
    26.3 (14.4) Muscle strengthening only −0.68 (3.28 to 1.89)
    26.7 (15.4) Aerobic only −0.57 (-2.06 to 0.92)
    25.0 (13.6) Aerobic and muscle strengthening −2.08 (−4.04 to −0.14)
Length of stay in 
hospital
Online supplemental table S10; cohort E 27.5 (16.5) Inactive (MET, 0) 1.0 (ref)†
    27.3 (15.1) Insufficiently active (MET, 1–<500) −0.18 (−1.47 to 1.11)
    24.8 (14.3) Active (MET, 500–<1000) −1.85 (−3.63 to −0.05)
    26.1 (14.3) Highly active (MET, ≥1000) −0.68 (−3.19 to 1.82)
Numbers in bold indicate significant differences (p<0.05).
*Regression models were adjusted for the age; sex; region of residence (Seoul Capital Area, Daegu/Gyeongbuk area and other areas); Charlson comorbidity index (0, 1 and ≥2); 
history of diabetes mellitus, tuberculosis, stroke and cardiovascular disease; body mass index (continuous; using the restricted cubic spline function); systolic blood pressure 
(continuous); diastolic blood pressure (continuous); fasting blood glucose (continuous); serum total cholesterol (continuous); glomerular filtration rate (≥90, 60–89 and ≤59 mL/
min); household income (low, middle and high); smoking (never, ex and current); alcoholic drinks (<1, 1–2, 3–4 and ≥5 days per week); medication for hypertension, diabetes 
mellitus and cardiovascular disease.
†Regression models were adjusted for the age (20–59, 60–69, 70–79 and ≥80 years); sex; region of residence (rural and urban); Charlson comorbidity index (0, 1 and ≥2); 
history of diabetes mellitus, tuberculosis, stroke and cardiovascular disease; body mass index (continuous; using the restricted cubic spline function); systolic blood pressure 
(continuous); diastolic blood pressure (continuous); fasting blood glucose (continuous); serum total cholesterol (continuous); glomerular filtration rate (≥90, 60–89 and ≤59 mL/
min); household income (low, middle and high); smoking (never, ex and current); alcoholic drinks (<1, 1–2, 3–4 and ≥5 days per week); medication for hypertension, diabetes 
mellitus and cardiovascular disease.
‡Severe COVID-19 consisted of admission to the intensive care unit, invasive ventilation or death.
MET, metabolic equivalent of task; RR, relative risk.
Table 4 Continued
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illness and COVID-19 related death. Interestingly, the length of 
hospital stay was shortened by approximately 2 days in patients 
who reported aerobic and muscle strengthening activities that 
met or exceeded the 2018 exercise guidelines (adjusted mean 
difference: −2.08 days) or those with MET 500–1000 MET 
min/week (adjusted mean difference: −1.85 days). The find-
ings of the study suggest that public health policies and strat-
egies to increase physical activity at the population level may 
reduce the risk of SARS- CoV-2 infection and minimise adverse 
consequences in patients with COVID-19. Encouraging individ-
uals to maintain recommended levels of physical activity during 
the COVID-19 pandemic should be promptly and vigorously 
considered at the public health level.
Key messages
What are the findings?
 ► Our results indicated that those who engaged in both 
aerobic and muscle strengthening activity according to 2018 
exercise guidelines had a lower risk of SARS- CoV-2 infection 
(adjusted relative risk (aRR), 0.85; 95% CI 0.72 to 0.96), 
severe COVID-19 illness (aRR 0.42; 95% CI 0.19 to 0.91) and 
COVID-19 related death (aRR, 0.24; 95% CI 0.05 to 0.99) 
than those who did not.
 ► Our findings reported that the recommended key target range 
of metabolic equivalent task (MET; 500–1000 MET min/week) 
was associated with the maximum beneficial effect size for 
reduced the risk of SARS- CoV-2 infection (aRR 0.78; 95% 
CI 0.66 to 0.92), severe COVID-19 illness (aRR 0.62; 95% CI 
0.43 to 0.90) and COVID-19 related death (aRR 0.17; 95% CI 
0.07 to 0.98). The length of stay in hospital was shortened 
about approximately 2 days in patients with both aerobic and 
muscle strengthening or with 500–1000 MET min/week.
How might it impact on clinical practice in the future?
 ► The findings of the study suggest that public health policies 
and strategies to increase physical activity at the population 
level may reduce the risk of SARS- CoV-2 infection and 
minimise adverse consequences in patients with COVID-19.
 ► Encouraging individuals to have active level of physical 
activity during the COVID-19 pandemic should be promptly 
and actively considered at the public health level.
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